Drugs / Budenofalk
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06922305 | Dec 2023 → Jan 2024 | IgA glomerulonephritis, autoimmune hepatitis | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budenofalk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06922305 ↗ |
| Known as | budesonide | “To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo®) and budesonide enteric-coated capsules (Budenofalk®).” NCT06922305 ↗ |
| Route | Oral | “subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.” NCT06922305 ↗ |